Last reviewed · How we verify
NCT04265417
Clinical Outcomes and Prognostic Factors of Robotic Assisted Rectal Cancer Resection Alone vs. Robotic Rectal Cancer Resection With Natural Orifice Specimen Extraction
trial testing Robotic Assisted Rectal Cancer Resection Alone in Rectal Neoplasms in 98 participants. Completed in 1 December 2016.
1 December 2016
Quick facts
| Lead sponsor | Taiyuan Li |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 98 |
| Start date | 6 January 2015 |
| Primary completion | 1 December 2016 |
| Estimated completion | 1 December 2016 |
Drugs / interventions tested
- Robotic Assisted Rectal Cancer Resection Alone
- Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction
Conditions studied
- Rectal Neoplasms — all drugs for Rectal Neoplasms →
- Robotic Surgery — all drugs for Robotic Surgery →
- Natural Orifice Specimen Extraction Surgery — all drugs for Natural Orifice Specimen Extraction Surgery →
Sponsor
Taiyuan Li
Who can join
Adults 18 to 75, any sex, with Rectal Neoplasms or Robotic Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Robotic rectal cancer resection with natural orifice extraction is a recently developed minimally invasive surgery for patients with rectal cancer. However, it's safety and feasibility remain undiscussed and controversial. This study reported the clinical outcomes and prognostic factors of robotic assisted rectal cancer resection alone vs. robotic rectal cancer resection with natural orifice extraction to discuss aforementioned question.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04265417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Neoplasms
Currently open trials in the same condition.
- NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
- NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
- NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
- NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting
Other Taiyuan Li trials
Trials by the same sponsor.
- NCT06405308 — Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early- · completed
- NCT04230772 — Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer · NA · unknown
- NCT06454253 — Short- and Long-term Outcomes of Robotic vs Laparoscopic Right Colon Cancer: a 10-year Single-center Retrospective Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04265417 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taiyuan Li
- Last refreshed: 18 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04265417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing